Free Trial

Immunocore (IMCR) Competitors

Immunocore logo
$33.56 +0.03 (+0.09%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$33.54 -0.02 (-0.04%)
As of 10/17/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCR vs. GRFS, NUVL, AXSM, LEGN, PCVX, MTSR, PTGX, TGTX, PTCT, and KRYS

Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), Vaxcyte (PCVX), Metsera (MTSR), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

Immunocore vs. Its Competitors

Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Grifols currently has a consensus target price of $10.30, indicating a potential upside of 6.74%. Immunocore has a consensus target price of $56.89, indicating a potential upside of 69.51%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Immunocore
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 1 mentions for Grifols and 0 mentions for Immunocore. Grifols' average media sentiment score of 0.79 beat Immunocore's score of 0.00 indicating that Grifols is being referred to more favorably in the media.

Company Overall Sentiment
Grifols Positive
Immunocore Neutral

Grifols has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Grifols has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.

Company Net Margins Return on Equity Return on Assets
GrifolsN/A N/A N/A
Immunocore -5.70%-5.40%-1.93%

84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$7.81B0.85$169.80M$1.178.25
Immunocore$310.20M5.45-$51.09M-$0.40-83.90

Summary

Grifols beats Immunocore on 11 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCR vs. The Competition

MetricImmunocoreMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.69B$3.44B$6.19B$10.56B
Dividend YieldN/A2.27%5.70%4.81%
P/E Ratio-83.9023.0185.5427.13
Price / Sales5.45481.75608.39130.24
Price / CashN/A46.9237.1060.81
Price / Book4.6610.4112.236.52
Net Income-$51.09M-$52.77M$3.33B$276.93M
7 Day Performance3.58%2.31%1.17%1.93%
1 Month Performance2.94%12.59%6.85%2.19%
1 Year Performance-2.39%11.18%58.93%34.62%

Immunocore Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCR
Immunocore
1.9638 of 5 stars
$33.56
+0.1%
$56.89
+69.5%
-2.4%$1.69B$310.20M-83.90320
GRFS
Grifols
3.7457 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+11.6%$6.41B$7.81B8.0823,822
NUVL
Nuvalent
2.8341 of 5 stars
$89.75
+1.9%
$118.89
+32.5%
-10.8%$6.35BN/A-18.3240Trending News
Analyst Forecast
Insider Trade
Analyst Revision
AXSM
Axsome Therapeutics
4.7305 of 5 stars
$121.15
-0.5%
$177.93
+46.9%
+37.1%$6.07B$385.69M-23.90380Positive News
Analyst Revision
LEGN
Legend Biotech
3.0839 of 5 stars
$32.85
+3.6%
$69.25
+110.8%
-25.4%$5.85B$627.24M-37.332,609News Coverage
Analyst Forecast
High Trading Volume
PCVX
Vaxcyte
2.3312 of 5 stars
$43.81
+0.3%
$106.25
+142.5%
-63.3%$5.67BN/A-10.66160News Coverage
Analyst Forecast
MTSR
Metsera
N/A$52.97
+0.2%
$55.75
+5.2%
N/A$5.55BN/A0.0081
PTGX
Protagonist Therapeutics
1.9306 of 5 stars
$79.17
-9.0%
$72.00
-9.1%
+65.0%$5.41B$434.43M113.10120Analyst Forecast
Insider Trade
High Trading Volume
TGTX
TG Therapeutics
4.5119 of 5 stars
$34.22
+1.4%
$49.00
+43.2%
+48.7%$5.36B$329M92.49290Positive News
PTCT
PTC Therapeutics
3.3414 of 5 stars
$66.06
-0.3%
$69.00
+4.5%
+68.7%$5.26B$806.78M9.481,410Analyst Revision
KRYS
Krystal Biotech
4.7806 of 5 stars
$184.74
+1.8%
$209.00
+13.1%
+6.2%$5.25B$290.52M37.55210News Coverage
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:IMCR) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners